Generalizations regarding pediatric and adult AML treatment approaches
| Component . | Pediatric . | Adult . |
|---|---|---|
| Induction cycles | 2 | 1 |
| CNS prophylaxis | Yes | No |
| Consolidation | Multi-agent (example in Table 5) | Single-agent cytarabine |
| Allogeneic transplant | High-risk cytogenetic features | Intermediate- and high-risk cytogenetic features |
| Component . | Pediatric . | Adult . |
|---|---|---|
| Induction cycles | 2 | 1 |
| CNS prophylaxis | Yes | No |
| Consolidation | Multi-agent (example in Table 5) | Single-agent cytarabine |
| Allogeneic transplant | High-risk cytogenetic features | Intermediate- and high-risk cytogenetic features |
CNS indicates central nervous system.